Researchers found that the prevalence of opioid prescriptions varied nearly 300% across the race/ethnicity-income gradient.
The rate of pediatric mortality associated with prescription and illicit opioids rose 3-fold between 1999 and 2016.
This rise in prescribing of prescription opioids in the last 2 decades of the 20th century occurred at a time during which medical professionals were urged to resort to prescription opioids to manage untreated and chronic noncancer pain.
The American Heart Association launched in December 2018 a 30 minute-long online course titled "Opioid Education for Healthcare Providers."
As the government shutdown drags in to its second month, physicians who treat opioid use disorders are being backed against a wall.
For the first time in history, Americans' risk for dying from an opioid overdose is higher than their risk for dying in a car accident.
Sandoz and Pear Therapeutics announced the launch of reSET-O, a new digital therapeutic for patients aged ≥18 years with opioid use disorder (OUD) currently under clinician care.
The Protecting Canadians from Unsafe Drugs Act passed into law in 2014 empowered the minister of health to recall a drug if they "believe that a therapeutic product presents a serious or imminent risk of injury to health."
More than two-thirds of drug overdose deaths in 2017 involved an opioid, with increases in overdose deaths from all opioids and synthetic opioids seen from 2016 to 2017.
reSET-O is intended for use as an adjunct to outpatient treatment that includes transmucosal buprenorphine (medication-assisted-treatment [MAT]) and contingency management for patients aged ≥18 years who are currently under clinician supervision.
Clinicians who are highly concerned about opioid misuse, addiction, and psychological dependence may be more confident but also more reluctant to prescribe opioids.
Addiction Medicine Consultation Improves Antibiotic Compliance in Patients with Opioid Use DisordersDecember 06, 2018
Patients with opioid use disorders who required hospitalization with lengthy antibiotic therapy had better outcomes with addiction medicine consultation.
In an effort to address the ongoing opioid crisis adequately, a set of measures complementing the current efforts at state and federal levels would need to be implemented for a more "coordinated and comprehensive approach" to the issue.
Seven key practice areas for the use of buprenorphine for the treatment of opioid use disorders were updated with new evidence-based recommendations.
While approved in Europe, Asia and Latin America, tianeptine is an unscheduled pharmaceutical agent in the US that has been linked to serious adverse events, including death, when used for recreational purposes.
The law restricting access to medication-assisted treatment with methadone to opioid treatment programs may have contributed to reducing opioid-related overdose death rates in the United States.
The vote was taken in a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee.
The guideline formulated by the Centers for Disease Control and Prevention in an effort to curb opioid overdose-related deaths included a recommendation for steep reductions in opioid doses for patients taking high doses of the drug for chronic pain.
A bipartisan bill meant to combat the United States' opioid abuse epidemic was signed into law on October 24, 2018.
The Centers for Disease Control and Prevention's "Guideline for Prescribing Opioids for Chronic Pain" may have contributed to a further reduction in several opioid prescribing practices.
A high percentage of post-9/11 veterans receiving Veterans Health Administration care were found to take concurrent prescription opioids and sedative hypnotics.
Failure of the Criminal Justice System to Accommodate Methadone Limits Addiction Recovery Among Incarcerated IndividualsSeptember 18, 2018
Despite the positive effects, just 55% of federal prison medical directors report offering methadone, and even fewer offer buprenorphine.
The integration of a Transitional Pain Service into a perioperative surgical home model could optimize perioperative pain control and opioid use, while reducing postdischarge hospital readmissions as well as the costs and disability linked to chronic postsurgical pain.
Accurate, transparent documentation is key in ensuring safe and appropriate opioid prescribing.
The new plan will break out the current guidance into 4 separate guidances.
Last year, the DEA proposed a 20% reduction in the manufacturing of controlled substances for 2018 compared to 2017.
Researchers Question DEA Hydrocodone Schedule Change in Light of Postoperative Prescribing Practice DataAugust 22, 2018
The US Drug Enforcement Administration rescheduled hydrocodone-containing analgesics from schedule III to schedule II in October 2014.
Chronic use of prescription opioids was correlated with support for the Republican candidate in the 2016 presidential election.
Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription NumbersAugust 22, 2018
Lowering the default number of opioid pills prescribed in an electronic medical record system can significantly decrease the amount of opioid medication prescribed after procedures.
Southern states have the 10 highest opioid prescribing rates in the country, while California, New York, and Virginia are among the bottom 10.
Check out what's trending
Medical Bag Articles
- FDA Warns About "Miracle" Young Blood Infusion Treatments
- Greater Income Inequality Is Associated With Worse Heart Failure Outcomes
- Emergency Department Care More Expensive in Full Medicaid Expansion States
- Burnout Predicts Clinician Turnover in Primary Care
- CDC: Severity of Influenza Season Low Through February 2, 2019